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Abstract
Objective To determine the relative costs and health effects of
interventions to combat cardiovascular disease, diabetes, and tobacco
related disease in order to guide the allocation of resources in developing
countries.
Design Cost effectiveness analysis of 123 single or combined prevention
and treatment strategies for cardiovascular disease, diabetes, and
smoking by means of a lifetime population model.
Setting Two World Health Organization sub-regions of the world:
countries in sub-Saharan Africa with very high adult and high child
mortality (AfrE) and countries in South East Asia with high adult and
high child mortality (SearD).
Data sources Demographic and epidemiological data were taken from
the WHO databases of mortality and global burden of disease. Estimates
of intervention coverage, effectiveness, and resource needs were drawn
from clinical trials, observational studies, and treatment guidelines. Unit
costs were taken from the WHO-CHOICE (Choosing Interventions that
are Cost-Effective) price database.
Main outcome measures Cost per disability adjusted life year (DALY)
averted, expressed in international dollars ($Int) for the year 2005.
Results Most of the interventions studied were considered highly cost
effective, meaning they generate one healthy year of life at a cost of
<$Int2000 (which is the gross domestic product per capita of the two
regions considered here). Interventions that offer particularly good
monetary value, and which could be considered for prioritised
implementation or scale up, include demand reduction strategies of the
Framework Convention for Tobacco Control (<$Int950 and <$Int200 per
DALY averted in AfrE and SearD respectively); combination drug therapy
for people with a >25% chance of experiencing a cardiovascular event
over the next decade, either alone or together with specific multidrug
regimens for the secondary prevention of post-acute ischaemic heart
disease and stroke (<$Int150 and <$Int230 per DALY averted in AfrE
and SearD respectively); and retinopathy screening and glycaemic
control for patients with diabetes (<$Int2100 and <$Int950 per DALY
averted in AfrE and SearD respectively).
Conclusion This comparative economic assessment has identified a
set of population-wide and individual strategies for prevention and control
of cardiovascular disease that are inexpensive and cost effective in low
resource settings.
Introduction
There is growing concern about the escalating burden of
non-communicable diseases and injuries throughout the world,
from both epidemiological and economic perspectives. Lives
lost to diseases such as cancer, cardiovascular disease, and
diabetes—together with the often longstanding disability
associatedwiththem—haveaneconomicimpactonhouseholds
and communities, both through the uptake of health services
and goods that diverts expenditure away from other possible
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RESEARCHuses and through loss of income or labour productivity.
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Despite these adverse consequences on health and economic
welfare, non-communicable diseases and injuries have been
neglected in international health and development initiatives.
The recent high level meeting on non-communicable diseases
at a special session of the United Nations General Assembly
and the subsequent political declaration
3 provides a political
mandate and an unprecedented opportunity to develop an
international policy framework for the prevention and control
of non-communicable diseases. A key action in support of this
strategy is the evidence on the interventions that work best at
the lowest cost in the prevention and control of
non-communicable disease and injuries, in developing regions
with a high disease burden.
In this series of articles we examine the relative cost
effectiveness of a comprehensive set of interventions and
strategiesforcombatingmajornon-communicablediseasesand
injury in economically developing regions of the world: this
paper covers cardiovascular disease and some of its key risk
factors(includingraisedbloodpressure,raisedbloodcholesterol,
and tobacco use), and the others assess respiratory disease
(asthmaandchronicobstructivepulmonarydisease),cancer(of
the breast, cervix, and colon or rectum), neuropsychiatric
disorders(schizophrenia,bipolaraffectivedisorder,depression,
harmful alcohol use, and epilepsy), sense organ diseases
(includingcataract,trachoma,refractiveerror,andhearingloss),
and road traffic injury.
4-8 Although this list leaves some gaps in
the diseases covered—musculoskeletal diseases and blood
disorders, for example—these analyses provide the largest
available database of comparable cost effectiveness estimates,
which a final paper uses to identify key priorities for the
prevention and control of non-communicable diseases and
injuries.
9 We also provide a companion paper that shows the
use of these methods at the country level (Mexico), as opposed
to the level of epidemiologically defined World Health
Organization sub-regions.
10
Cardiovascular disease is the single largest cause of mortality
worldwide,accountingfor17milliondeaths,equivalentto29%
of all deaths annually. We cover primary prevention efforts at
both the population level (such as tobacco control measures,
reduced dietary salt intake) and at the individual level (such as
control of hypertension or blood cholesterol with drugs and
combination drug therapy for individuals at high risk of a
cardiovascular event) as well as secondary and tertiary
preventionormanagementofischaemicheartdiseaseandstroke.
Wealsoincludethemanagement(butnotprevention)ofanother
major cardiovascular risk factor, namely diabetes and its
associatedcomplications(whichaccountformorethananother
million deaths worldwide each year). Intervention cost
effectiveness results for two further cardiovascular risk
factors—unhealthy diet and physical inactivity—have recently
been reported elsewhere for a set of (mainly middle income)
countries,
11 but are not integrated into our analysis because of
differences in the modelling environment adopted.
Methods
This analysis follows the standardised methodology on cost
effectivenessanalysissetforthbytheWHO-CHOICEproject
12-14
and builds on previous analyses of public health interventions
tolowersystolicbloodpressureandcholesterol
15andoftobacco
use.
16 We provide an overview of the methods and data used to
carry out and update these earlier analyses and a more detailed
descriptionofmodellingassumptionsanddatasourcesadopted
for previously unpublished analyses (management of
cardiovascular disease and diabetes).
In common with other papers in this and a previous
WHO-CHOICE series,
17 cost effectiveness modelling was
carried out for two WHO reporting sub-regions, one in Africa
(countries with high child and very high adult mortality,
henceforth denoted “AfrE”) and the other in South East Asia
(countries with high child and adult mortality, henceforth
denoted “SearD”). Information on the countries pertaining to
these two WHO epidemiological sub regions can be found in
appendix 1 on bmj.com. Results for other WHO reporting
regions can be viewed at the WHO-CHOICE website (www.
who.int/choice); the models used have been designed for
subsequent contextualisation by individual member states.
Interventions
Arangeofstrategiesforpreventionandcontrolwereconsidered;
where it was clinically meaningful to do so, we also assessed
combination strategies. Table 1⇓ lists all single interventions
included in this analysis. Interventions were selected according
tothestrengthofevidencesupportingtheireffectivenessaswell
asrecommendationsfrompublishedguidelines(seeappendices
2–4 on bmj.com). Effectiveness of interventions was sought
using the best available evidence reported in international
literature. Source data for intervention effectiveness included
meta-analyses, systematic reviews, clinical trials, and
observational studies (appendices 2–4).
Tobacco control strategies—Prevention of cardiovascular
disease—as well as lung cancer and chronic obstructive
pulmonary disease—via enhanced tobacco control efforts
included key strategies of the WHO Framework Convention
for Tobacco Control to reduce demand (current and increased
taxation, legislated restrictions on smoking in public places,
comprehensive bans on advertising of tobacco products,
information dissemination through health warning labels,
counter advertising, and various consumer information
packages). Personal health interventions include nicotine
replacement therapy and physician advice. Appendix 2 on
bmj.com documents the efficacy, non-compliance, and target
coverage levels of these measures.
Cardiovascular disease interventions—Primary prevention
strategies cover both population-wide and individual level
interventionsaimedatreducingtheriskofcoronaryheartdisease
and cerebrovascular disease through the voluntary or regulated
reduction in dietary salt intake, control of blood pressure and
cholesterolwithdrugs,andcombinationdrugtherapyforpeople
at an absolute (as opposed to relative) risk of experiencing a
cardiovascular disease event over the next 10 years >25%.
15
The multidrug regimen consisted of four generic drugs—a β
blocker, a diuretic, a statin, and aspirin (because of the risk of
gastrointestinalbleedinginagroupofpatients,debatecontinues
about the overall risk:benefit ratio of aspirin in primary
prevention of cardiovascular disease). Management strategies
focus on acute care of myocardial infarction and stroke in the
inpatientsetting,coveringbothsurgicalanddruginterventions.
Secondary and tertiary prevention interventions concern the
long term treatment of patients with a previous myocardial
infarction or stroke with the aim of reducing the risk of a
subsequent event and the occurrence of more severe stages of
the disease. Interventions for the management of symptomatic
left ventricular systolic dysfunction in patients with a previous
myocardial infarction are also included since this condition is
commoninpatientswithapreviousmyocardialinfarction.Heart
failure interventions are intended for patients in stage C of the
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RESEARCHdisease according to the American College of Cardiology and
American Heart Association classification of chronic heart
failure progression.
18 Appendix 3 on bmj.com provides a list of
the cardiovascular disease intervention strategies assessed,
together with estimates of their effect on reducing the risk,
incidence or fatality of disease. All interventions were assessed
at a treatment coverage level of 80%.
Diabetes interventions—For managing type 1 and type 2
diabetes,wefocusedondiabetescasesandthesequelaecovered
by the Global Burden of Disease study (blindness due to
retinopathy, neuropathy, and diabetic foot and amputation).
19
Key interventions assessed were standard and intensive
approaches to glycaemic control, screening for retinopathy and
subsequent treatment as needed, and screening for neuropathy
plus associated preventive foot care (appendix 4 on bmj.com
provides a more detailed description of these interventions and
how they were modelled). A uniform 80% treatment coverage
was also used in order to facilitate comparison with
cardiovascular disease results.
The large majority of interventions analysed are drug based.
Current availability of drugs to treat chronic diseases ranges
from 36% to 55% in low and middle income countries in the
publicandprivatesector,respectively.
20InBangladesh,Malawi,
and Nepal—specific countries in the regions studied—the
availabilityofchronicdiseasedrugsrangesfrom5%to37.5%.
21
Cardiac units to perform angioplasty are available in hospitals
in the following countries in AfrE: Kenya, Tanzania,
Mozambique, South Africa, and Ivory Coast.
22 Taking India as
a country example for SearD, there are 220 hospitals capable
of performing percutaneous angioplasty, located in the main
cities.
23
We have not been able to include all possible interventions in
thisanalysisbecauseoflackofinformationoneithertheimpact
ofthetreatmentortheunderlyingepidemiologicaldatarequired
for determining treatment effectiveness. Renal disease and
cardiovascular disease, for example, were not specified as
sequelae for diabetes in the Global Burden of Disease study of
2004,sowehavenotassessedkeyinterventionsrelatingtothem
(including the prevention of diabetes through reduction of risk
of cardiovascular disease, management of cardiovascular
complicationsamongdiabeticpatients,andtreatmentofdiabetic
nephropathy with angiotensin converting enzyme (ACE)
inhibitors). Other excluded interventions that may have a
positive health impact include those for preventing rheumatic
heart disease or angina pectoris and treatment of refractory end
stage heart failure, early diastolic and systolic dysfunction, and
concomitant diseases such as arrhythmia and cardiac valve
disorders. The treatment of complications of acute events
(hypotension, pulmonary congestion, cardiogenic shock, etc)
and diagnostic or prognostic interventions performed during
management of an acute event were beyond the scope of this
analysis.
Modelling approach
WHO-CHOICEemploysanepidemiological,populationbased
approach to the assessment of health outcomes (see general
appendix on bmj.com). Along with background birth,
population, and mortality rates, observed rates of disease
incidence, prevalence, and mortality—drawn from the Global
BurdenofDiseasedatabase
19andshownintable2⇓—areentered
intoastatetransitionmodelinordertoestablishthetotalnumber
of years of healthy life experienced over the (100 year) lifetime
ofadefinedpopulation.
24Themodelissuccessivelyruninorder
to calculate the additional number of healthy years lived by the
population—equivalenttothenumberofdisabilityadjustedlife
years (DALYs) averted—after the implementation of a single
or combined health intervention, compared with a baseline or
null scenario of no interventions for the disease in question.
Thisnullscenariowasdeterminedbybackcalculatingincidence
andcasefatalityratesusinginterventioneffectsizesandcurrent
coverage rates (that is, epidemiological rates are adjusted
upwards to reflect the absence of any effective intervention).
Interventions are taken to be implemented for a period of 10
years, after which epidemiological rates go back to their
counterfactual level of no intervention. Consistent with the
WHO Global Burden of Disease study, DALYs are discounted
(at 3% per year) and age weighted.
Thespecificbenefitsoftobaccocontrolmeasuresonpopulation
health were estimated through the impact of reduced smoking
on the tobacco attributable incidence of cardiovascular disease,
respiratorydisease,andmortalityfromvariousformsofcancer.
Wemodelledtheincreaseintaxationthatwouldreducesmoking
prevalenceby10%onthebasisofdataontobaccotaxationfrom
previous WHO and World Bank studies.
25 The effect of price
changesonconsumptionwasestimatedfrominformationabout
priceelasticitiesofdemandfortobaccoproducts(thepercentage
change in consumption resulting from a 1% increase in price).
For a 10% rise in price due to tobacco taxes, consumption
generally falls by 8–10% in low and middle income
countries.
26 27 We calculated that the prevalence elasticity (the
percentage change in smoking prevalence resulting from a 1%
increase in price) was half the total price elasticity of demand,
because at least half of the estimated effect on the demand for
tobacco products results from a reduction in smoking
prevalence.
28 Given that current smoking prevalence is a poor
proxy for the accumulated health risks of tobacco use, we used
the smoking impact ratio as a marker for cumulative smoking
risk.
29 The smoking impact ratio captures the accumulated
hazardsofsmokingbyconvertingthesmokersinthepopulation
analysed into equivalents of smokers in a reference population,
where hazards for other diseases have been measured. The
reference population used in our case was the CPS II cohort.
30
We used relative risks in estimating tobacco attributable
morbidityandmortality.Interventioneffectivenesswasassessed
through changes in smoking impact ratio and relative risks of
mortality and morbidity from tobacco related diseases per unit
of smoking impact ratio (see table 3⇓ for relative risk values
used in the analysis).
For the primary prevention of cardiovascular disease, health
effects were modelled by stochastically simulating populations
specific for age and sex with the observed baseline values of
ischaemic heart disease and stroke incidence and the observed
distribution of risk factors (systolic blood pressure, serum
cholesterol, body mass index, and prevalence of long term
smokers
15)(seetable2⇓).Incidenceriskisapportionedbetween
individuals using estimates of the relative risk of modelled risk
factors on cardiovascular events (table 3⇓). Population level
incidence of ischaemic heart disease and stroke is recalculated
after applying the impact of the intervention on the individual
risk factor values for those receiving the intervention.
For acute myocardial infarction and stroke, health effects were
modelled through their impact on case fatality in hospital and
after discharge up to 28 days after the event (out of hospital
case fatality rates were assumed to remain unchanged).
Secondary and tertiary prevention interventions were modelled
through their impact on post-28 day case fatality rates for each
conditionandtherateofcomplicationsattributabletoischaemic
heart disease (angina, congestive heart failure). The interaction
inriskbetweenischaemicheartdiseaseandstrokewasmodelled
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RESEARCHusingestimatesofrelativeriskofstrokeforthosewithprevious
ischaemic heart disease and vice versa from published
epidemiological studies (see appendix 3 on bmj.com).
Finally, for managing diabetes and its complications,
interventionhealtheffectswereexpressedintermsofcomposite
disability weights that reflect varying distributions of different
healthstates(diabeteswithoutcomplications,neuropathy,lower
extremity amputation, background retinopathy, proliferative
diabetic retinopathy plus macular oedema, and blindness due
to retinopathy). These six disease states reflect the progression
of diabetes along the long term consequences of eye and foot
disease. To derive a composite disability weight for each
intervention, we simulated the evolution of a closed population
cohort of people aged >15 years over 100 years via a health
state model (MiniMod, see appendix 4 on bmj.com for further
details).
Intervention costs
We pursued an ingredients approach to costing, meaning that
information on the quantities of all services and goods required
for the delivery of an intervention as well as data on their unit
costsweresought.Thetotalcostofaninterventionistheproduct
of these quantities and their respective unit costs. Particular
attention was given to maintaining consistency of the
information on resource use with that described in the articles
selected as source of effectiveness for the interventions. Costs
were calculated for a 10 year period of implementation
(subsequently discounted annually by 3%) and expressed in
international dollars for 2005. An international dollar is a
hypotheticalcurrencythatisusedasameansofcomparingcosts
taking into account differences in purchasing power. One
internationaldollar($Int1)buysthesamequantityofhealthcare
resources in Kenya or India as it does in the United States. As
reference, $Int1 is worth US$0.44 and US$0.32 in sub-Saharan
AfricaandSouthEastAsiaregions,respectively.Weconsidered
bothpatientandprogrammecosts.Patientcostsincludeddrugs,
laboratory tests, and inpatient and outpatient visits. A detailed
description of resource quantities used at the patient level is
given for each diabetes intervention in appendix 4 and for each
cardiovascular disease intervention in appendix 5 on bmj.com.
Programme costs included all resources required for the
implementation and maintenance of interventions, such as
administration and planning, media and communications, law
enforcement activities, training, evaluation, and monitoring.
Population-wide measures for reducing salt intake or tobacco
use involve costs exclusively at the programme level and are
documented elsewhere.
25 Costing of these interventions was
performedusingWHO-CHOICEprogrammecostingtemplates
and world regional pricing databases (www.who.int/choice).
Handling of cost effectiveness data and
uncertainty
Dividing the total implementation costs of each intervention by
its effects generates a simple cost effectiveness ratio, relative
to a comparator situation of no intervention. In addition to
averagecosteffectivenessratios,incrementalcosteffectiveness
ratios are reported for the successive set of interventions that
would be selected at expanding levels of resource availability,
starting with the intervention with the lowest cost per DALY
averted,thenmovingtothenextmostcosteffectivecombination
intervention out of the remaining available set of interventions.
An intervention that is more costly or less effective than other
more efficient interventions is denoted as dominated.
Allinterventionsareimbuedwithacertaindegreeofuncertainty.
To handle this aspect of reporting for such a wide range of
interventions, we first placed intervention results on a
logarithmicscale,withaviewtoascertainingorderofmagnitude
differences in cost effectiveness (such as $Int10–100 versus
$Int100–1000 per DALY averted). Secondly, we categorised
results according to a defined set of cost effectiveness
thresholds: WHO-CHOICE denotes an intervention as “cost
effective” if it produces a healthy year of life for less than three
timesthegrossdomesticproduct(GDP)percapita,andas“very
cost effective” if it produces a healthy year of life for less than
the GDP per capita. Finally, for the subset of intervention
strategies that were not dominated by others and therefore fall
on the cost effectiveness frontier, we undertook a probabilistic
uncertainty analysis using the MCLeague software program.
32
We also assessed the impact of removing age weights or
discountingonbaselineresultsviaonewaysensitivityanalysis.
Results
Atotalof123singleandcombinedinterventionstrategieswere
assessed (36 for tobacco control, 77 for cardiovascular disease,
and 10 for diabetes). The annual cost, effect, and cost
effectiveness for all interventions are provided in appendix 6
on bmj.com, and are shown graphically in figures 1⇓ and 2⇓.
Costs ($Int) and effects (DALYs averted) have been calculated
for a standardised population of one million people to allow for
easier comparison between different geographical regions.
Intervention effects
The health impact of assessed interventions at the population
level varied dramatically, ranging from 10 to >7000 DALYs
averted annually per million population (see figs 1⇓ and 2⇓).
The largest effects were found among drug strategies directed
towards the prevention and control of raised blood pressure or
cholesterol. At a treatment coverage level of 80%, drug
treatment for those with hypertension (systolic blood pressure
>140 or >160 mm Hg) and combined drug therapy for people
witha5–35%riskofexperiencingacardiovasculareventinthe
next 10 years are estimated to avert between 2000 and 7000
DALYs per million population in both the African and South
East Asian sub-regions (so in India alone, with over a billion
inhabitants, this would equate to at least 2–5 million DALYs
averted). A comprehensive set of demand reduction measures
for tobacco control—such as that contained in the MPOWER
package(acronymfortheactivitiesmonitor,protect,offer,warn,
enforce,andraise)
33—alsohasthepotentialtoyieldlargehealth
benefits, particularly where the tobacco epidemic is more
advanced(suchasinSouthEastAsiansub-regionSearD,where
population level health gains are five times greater than in the
African sub-region).
Acute care and secondary prevention strategies for people who
have had a heart attack or stroke fall into the range of 10–1000
DALYs averted per million population, and again show greater
expected benefits in the South East Asian population (because
of the higher prevalence of disease, table 2⇓). For acute
myocardial infarction, treatment in hospital with aspirin alone
averts 59 DALYs per million population in the African
sub-region and 243 in the South East Asian sub-region. Health
gainsaredoubledwhenthisstrategyiscombinedwithprovision
of thrombolysis with streptokinase, and tripled if percutaneous
transluminal coronary angioplasty can also be made available;
marginal additional health gains can be secured by also making
use of antihypertensive drugs (β blockers and ACE inhibitors).
Acute treatment for stroke with aspirin or by provision of an
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RESEARCHorganised stroke unit generates modest outcomes (<50 DALYs
saved per million population). For secondary prevention, the
mosteffectivemeasuresassessedrevolvedaroundmultipledrug
therapy: for post-acute stroke, aspirin and a statin, with the
addition of an ACE inhibitor and diuretic for greatest gains
(>700 DALYs averted per million population); for post-acute
ischaemic heart disease, a combination of aspirin, β blocker,
statin, and ACE inhibitor. Use of loop diuretics, exercise
training, and drug treatment of hypertension was estimated to
be the single most effective option for reducing the mortality
riskamongpatientswithcongestiveheartfailure(seeappendices
3 and 5 on bmj.com).
Concerning the management of diabetes and the specified
sequelae included in the analysis, the most effective strategy of
those assessed was intensive glycaemic control combined with
a programme of retinopathy screening and photocoagulation
(1529 and 3710 DALYs averted per million population in AfrE
and SearD, respectively). On its own, intensive glycaemic
control was found to generate 19–23% more health gain than
conventional glycaemic control (appendix 6 on bmj.com). The
programme of neuropathy screening and preventive foot care
was the least effective strategy.
Intervention costs
Total costs of implementing an intervention over a 10 year
period were annualised and converted into per capita estimates
for easier interpretation. From this public health perspective,
the costs associated with delivering these interventions at a
scaled up level of coverage are not high, with most falling well
below$Int1percapita(seefigs1⇓and2⇓).Someinterventions
are very low cost (<$Int0.20 per capita), not just population
based measures such as salt reduction and tobacco taxation, but
alsomanyoftheacutecareandsecondarypreventionmeasures
aimedatindividualswhohavealreadyexperiencedaheartattack
or stroke. Although the overall costs of these interventions are
similarly low, it must be remembered that there are large
differences in the number of exposed or treated people (for
example, acute myocardial infarction care is targeted on less
than 1% of the total population, compared with 80% for
regulatory tobacco control measures). This explains why drug
treatment strategies for individuals at an elevated but not very
high risk of cardiovascular disease (such as those with systolic
bloodpressure>140mmHgorserumcholesterol>5.7mmol/L)
are among the most expensive strategies to implement at the
population level ($Int1–3 per capita); there are simply a lot of
people who meet these criteria (>25% of all men aged ≥60
years, for example). The total number of beneficiaries and the
annual cost per treated case for the full range of cardiovascular
disease treatment strategies are presented in appendix 6, from
which it can be seen that costs per treated case for acute care
interventionsgenerallyfallintherangeof$Int500–3000,while
population-wide primary prevention strategies cost $Int30–80
percase.Anintensiveglycaemiccontrolprogrammeforpeople
with diabetes is also relatively costly (>$Int2 per capita), due
to the many resources that are consumed in its implementation
(as described in appendix 4).
Intervention cost effectiveness
As shown by the diagonal bands in figures 1⇓ and 2⇓, average
cost effectiveness ratios were found to fall in the range of
$Int100–10 000 per DALY averted (two orders of magnitude
difference). Within the more restricted range of $Int100–1000
perDALYaverted,interventionsappearforeachofthediseases
and risk factors considered in the analysis. Using average GDP
per capita (which in both sub-regions is close to $Int2000) as a
threshold for considering an intervention to be highly cost
effective, we found the great majority of interventions assessed
here meeting that criterion. Exceptions include the treatment of
acute myocardial infarction with β blockers or ACE inhibitors
alone,treatmentofacuteischaemicstrokewithaspirin,provision
oforganisedstrokeunitcare,andnicotinereplacementtherapy;
these interventions have a cost effectiveness ratio more than
three times the average per capita income in these regions
(>$Int6000) and are considered relatively cost ineffective.
In the African sub-region, the most cost effective interventions
(average cost effectiveness ratio <$Int200 per DALY averted)
were those that targeted individuals at >25% absolute risk of
having a cardiovascular event in the next 10 years, either on
their own or in combination with an efficient set of secondary
preventionmeasures.Thesewerealsoamongthemostefficient
interventions in the South East Asian sub-region, as well as
other strategies such as tobacco control measures, retinopathy
screening and treatment, and the management of congestive
heart failure with diuretics. Even if the cost of implementing
these interventions were doubled and effect sizes halved, the
average cost effectiveness ratios would still be <$Int1000 per
DALY averted.
The costs, effects, and cost effectiveness of all the “dominant”
interventions—thatis,thosethataremoreeffectiveorlesscostly
than other competing strategies—are shown in table 4⇓. The
interventions are presented in descending order, starting with
the most cost effective intervention in each disease cluster. As
more resources become available, other cost effective
interventions could be purchased. These next best options, at
situations of increased resource availability, are presented in
thetableindownwardsequence.Incrementalcosteffectiveness
ratios are also provided for each cluster of interventions, which
give the additional cost needed to secure one extra healthy life
year as successively less cost effective strategies are entered
into the mix. The probabilistic uncertainty analysis depicted in
figures 3⇓ and 4⇓ also show that these interventions remain
highly cost effective (cost effectiveness ratio <$Int2000 per
DALY averted) even after allowing for plausible variations in
costs and effects. A one way sensitivity analysis revealed that
removing age weights from the estimation of DALYs has a
modest positive impact on baseline results (average cost
effectivenessratiovaluesfallby8–25%);removingdiscounting
as well has a larger influence, increasing health outcomes for
treatment strategies by at least 40% and preventive measures
by more than 100% and thereby lowering cost effectiveness
values markedly (by a third to a half).
Discussion
Main findings
We have quantified the health effects, costs, and cost
effectiveness of a broad range of preventive and management
strategiesforreducingtheriskofcardiovasculardiseaseburden,
as well as a number of specific treatment measures for diabetes
and its complications. These results were obtained by means of
adynamicpopulationmodel,usingconsistentdemographicand
epidemiological data of the populations studied, allowing a
more precise prediction of the behaviour of the disease and
consequentlyofthehealthandeconomicimpactofthestrategies
studied.
Ourresultsprovideimportantinformationaboutpreventionand
management of cardiovascular disease in the two settings
studied, for both individual and population health. From the
individualviewpoint,theeffectivenessofinterventionsincreases
with the risk of the target population, with greatest gains per
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RESEARCHbeneficiary seen among the more effective strategies for
managing an acute cardiovascular disease event (management
of acute myocardial infarction with aspirin, blood pressure
loweringdrugs,andreperfusionwithpercutaneoustransluminal
coronary angioplasty). The treatment effect decreases as the
risk lowers, such that the lowest health gain per beneficiary is
attained through health promotion interventions targeting
susceptible individuals regardless of their risk factor or disease
status.
Fromapopulationhealthperspective,however,thesmalleffects
achieved by strategies targeting large, lower risk groups may
end up generating more overall health gain (as seen from this
analysis). As a consequence, from this perspective, health
promotion and primary prevention interventions, such as
combined hypertension and lipid lowering drugs plus aspirin
for individuals with a cardiovascular disease risk >25%, are
more effective than acute care and secondary prevention
interventions. Thus, the combination of individual and
population-wide strategies is required for a complete risk
reduction.
34 In this analysis these combinations (cardiovascular
diseaseinterventionsCVD-69–71,73–76,and78(seeappendix
6 for explanation)) were highly effective, averting more than
5000 DALYS annually per million population.
With respect to the cost of interventions, the cost per individual
increases as the risk level of the target group rises, mainly due
to the increased need for and complexity of healthcare services
(particularly inpatient hospital admission). At the other end of
the spectrum, population-wide measures aimed at reducing
tobaccouse,bloodpressure,andbloodcholesterolmakenouse
of healthcare facilities and therefore tend to be inexpensive to
implement.
Differences between the individual and population health
perspectives are reconciled when comparing interventions in
terms of their cost effectiveness (total costs divided by total
health gains). Our analysis indicates that most of the
interventions studied were highly cost effective, meaning they
would generate one healthy year of life at a cost of less than the
GDP per capita of the region in question (around $Int2000 in
the two regions considered here). Out of the large collection of
highly cost effective options, we identified which interventions
offer the best monetary value and which could be considered
for prioritised implementation or scale up, including demand
reduction strategies of the Framework Convention for Tobacco
Control,combinationdrugtherapyforindividualswitha>25%
chance of experiencing a cardiovascular disease event over the
next decade, and the combination of this population-wide
intervention with individual treatment of acute myocardial
infarction with drugs and reperfusion or with individual
multidrug regimens for the secondary prevention of post-acute
ischaemic heart disease and stroke. These interventions have
beenidentifiedasessentialcardiovasculardiseaseinterventions
that need to be financed as a first step to universal coverage.
34 35
Inthecaseofdiabetes,wehaveidentifiedretinopathyscreening
and glycaemic control for patients with diabetes as a cost
effectiveinterventionthatneedstobegivenpriority,inaddition
tointerventionssuchascardiovascularriskreductionindiabetes
and screening for albuminuria for prevention of nephropathy
that have been identified in other studies as cost effective
options.
36-41 Although intensive glycaemic control was highly
cost effective in the regions analysed, the effects of this
intervention may vary within different patient subgroups (men
vwomen,age,baselineHbA1c,comorbidities),
42sotheseresults
should be interpreted with caution.
Policy implications
The findings from this economic analysis should be used as a
guide for decision makers and are not prescriptive, since other
factors—such as the epidemiology of the disease, health
infrastructure, and government support—should be taken into
account. In particular, this analysis provides results at regional
levels,usingregionalinformationonepidemiologyandresource
use. Although the WHO-CHOICE framework provides results
that are generalisable across settings, it should be recognised
thatinformationonepidemiologyandcostsusedcanbeexpected
to vary among countries within the same region, even more so
among countries from different regions. Decision makers who
wish to contextualise these results to their specific country
shouldassesstheneedtomodifytheseparameters(effectiveness,
costs, coverage, disability weights, etc) based on national data
in order to more accurately reflect efficiency considerations in
theirowncontext.Countrylevelcontextualisationofthevarious
analytical models—as has been undertaken in Argentina,
Estonia, Mexico, and Vietnam, for example
10 43-45—provides a
useful process for generating more local evidence for national
decision makers and fostering policy dialogue.
To allow for a meaningful comparison of all interventions
analysed across the different disease clusters, the standard
approach taken here was to report results at an 80% coverage
level. Adopting a uniform coverage level is relevant for
identifying the pattern of best choices of interventions in terms
of efficiency. However, implementation at this coverage level
mightnotbefeasibleforsomeinterventionsincertainlocations.
Modellers and decision makers can adjust coverage level and
other parameters during country contextualisation of this
analysis to better reflect the situation at a country level.
The health and economic impact of public health interventions
could be broad and may fall outside the health sector. The
assessment of outcomes of public health interventions here
analysed (such as demand reduction strategies for tobacco and
food salt reduction via legislation) has been limited to benefits
within the health sector, following the perspective and
methodology of cost effectiveness analysis. Other non-health
benefits that might be important, such as productivity gains, as
wellasthequantificationofcostconsequencesoutsidethehealth
sectorwouldneedtobeexploredbymeansofotherintersectoral
approaches.
46
Study limitations and future research
Our results represent aggregate regional estimates based on the
bestavailablesourcesinpublishedinternationalliterature.Many
of the effectiveness and some of the resource use values used
inthisanalysisarederivedfromestimatesorstandardsobtained
from developed countries in the absence of data from the less
developed regions analysed. Although other data used in this
analysis—such as disease epidemiology, demography,
intervention use, adherence, and capacity use—are region
specific and contribute to more precise cost effectiveness
estimates, similar results in specific locations may not be
assumed since outcomes or resource use estimates may vary
fromdevelopedtodevelopingcountries.Forinstance,61%case
fatality reduction with percutaneous transluminal coronary
angioplasty may not be achievable in some hospitals in
developingcountries.Althoughwehaveperformeduncertainty
analysisaroundkeyeffectandcostestimates,forbetterprecision
on these estimates, analysts in a specific low or middle income
country are encouraged to adjust parameters to reflect context
specificsituationsbasedonlocalqualitydata.Resultsfromhigh
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RESEARCHquality research in developing countries would be required for
this purpose.
Because of the sheer number of assessed interventions, it was
practicable only to show graphically probabilistic uncertainty
estimates for interventions that are less costly or more effective
than other less efficient interventions, thereby omitting other
interventionswithalowerbutstillrealprobabilityofbeingcost
effective at defined threshold levels.
Finally, and with the exception of salt reduction, we have not
been able to integrate here the impact of diet and physical
activity in addressing the burden of cardiovascular disease. A
recent collaborative study between the Organisation for
Economic Co-operation and Development (OECD) and the
WHO—ofinterventioncosteffectivenessfortacklingunhealthy
diets, physical inactivity, and obesity—adopted a
micro-simulation approach to disease modelling, assumed a
different implementation period, and compared intervention
impactwiththecurrentsituation(ratherthannointervention),
11
thereby hindering comparability with our study results.
Nevertheless, results from this study of interventions for
improveddietandphysicalactivityindicatethatthereareseveral
population based prevention policies—covering improved
awareness and information, appropriate fiscal measures, and
enhanced regulatory mechanisms—that, from an efficiency
pointofview,mightusefullybeaddedtothemeasuresidentified
fortheriskfactorsexplicitlyconsideredhere(tobaccouse,high
blood pressure, and elevated cholesterol).
In terms of future research requirements, the standout issue is
the need for a more complete single model that is capable of
simultaneously dealing with all cardiovascular risk factors and
their interactions. Since diabetes increases the risk of
cardiovasculardisease,forexample,theimpactofinterventions
forthetreatmentofhyperglycaemiainreducingthisriskshould
beassessed.Thisanalysisandpreviouscosteffectivenessstudies
have focused on the influence of traditional risk factors in the
development of cardiovascular events, but—because of the
increasing prevalence of diabetes—an integrated
diabetes-cardiovascular disease approach should be pursued in
future.
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RESEARCHTables
Table 1| List of single interventions considered in cost effectiveness analysis of strategies to combat cardiovascular disease, diabetes,
and tobacco related disease in WHO sub-Saharan African sub-region AfrE and South East Asian sub-region SearD
Description Intervention and code
Tobacco control use
Current excise taxation (~40%) TOB-1: Raise taxes on tobacco
Increased excise taxation (60%) TOB-2: Raise taxes on tobacco
Comprehensive ban on advertising of tobacco products TOB-3: Enforce bans on tobacco advertising
Clean indoor air in public places through legislation and enforcement TOB-4: Protect people from tobacco smoke
Counter-advertising and warning labels TOB-5: Warn about the dangers of tobacco
Nicotine replacement therapy (TOB-6), brief advice (TOB-7), counselling (TOB-8) TOB-6–8: Offer to help quit tobacco use
Cardiovascular disease
Primary prevention, population-wide:
Cooperation between government and food industry for stepwise decrease in salt content
of processed foods and for labelling
CVD-1: Salt reduction in processed foods via voluntary agreement
with industry
Legislation to decrease salt content in processed foods and appropriate labelling CVD-2: Salt reduction in processed foods via legislation
Health education through broadcast and print media focusing on body mass index and
cholesterol concentrations
CVD-3: Health education through mass media
Primary prevention, targeting individuals:
Standard regimen of β blocker + diuretic for systolic blood pressure >160 mm Hg (CVD-4)
or >140 mm Hg (CVD-5)
CVD-4, 5: Hypertension treatment and education
Statins for total cholesterol concentrations >6.2 mmol/L (CVD-6) or >5.7 mmol/L (CVD-7) CVD-6, 7: Treatment for high cholesterol concentrations and
education
Statin, diuretic, β blocker, + aspirin for cardiovascular risk of 35% (CVD-8), 25% (CVD-9),
15% (CVD-10), or 5% (CVD-11)
CVD-8–11: Treatment based on absolute risk of a cardiovascular
event* in next 10 years
Acute treatment:
Aspirin during emergency and inhospital phases of MI CVD-14: Antithrombotic therapy
ACE inhibitor during emergency and inhospital phases of MI CVD-16: Anti-ischaemic therapy
β blocker during inhospital phase of MI CVD-18: β blockade therapy
Streptokinase during emergency phase of MI CVD-21: Pharmacological reperfusion
Coronary percutaneous intervention (balloon angioplasty) during emergency phase of MI CVD-22: Surgical reperfusion
Acute stroke and rehabilitation care coordinated by multidisciplinary team and provided in
hospital
CVD-28: Stroke unit care
Aspirin during emergency and inhospital phases of ischaemic stroke CVD-24: Antithrombotic therapy
Secondary and tertiary prevention:
Long term aspirin treatment after MI CVD-15: Antithrombotic therapy with aspirin
Long term ACE inhibitor treatment after MI CVD-17: ACE inhibitor therapy
Long term β blocker treatment after MI CVD-19: β blockade therapy
Long term statin treatment after MI CVD-20: Lipid lowering therapy
Exercise programme after MI, consisting of unsupervised and group exercise training sessions
(mainly endurance training) with initial evaluation by physician
CVD-23: Cardiac rehabilitation, exercise
Long term ACE inhibitor + diuretic treatment after ischaemic stroke CVD-27: Blood pressure lowering therapy
Long term aspirin treatment after stroke CVD-25: Antithrombotic therapy
Long term statin treatment after ischaemic stroke CVD-26: Lipid lowering therapy
Long term diuretic treatment after MI for patients with established heart failure CVD-29: Diuretic therapy
Long term ACE inhibitor treatment after MI for patients with established heart failure CVD-30: ACE inhibitor therapy
Long term β blocker treatment after MI for patients with established heart failure CVD-31: β blockade therapy
Exercise programme for established heart failure, consisting of unsupervised and group
exercise training sessions (endurance and resistance training) with initial evaluation by
physician
CVD-32: Exercise training
Diabetes and complications
Oral sulphonylureas or insulin to diabetic patients for a goal of HbA1c <7% DM-3: Intensive glycaemic control
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RESEARCHTable 1 (continued)
Description Intervention and code
Detection of diabetic proliferative retinopathy and macular oedema and treatment with laser
photocoagulation if suitable
DM-4: Retinopathy screening and photocoagulation
Classification of feet at risk for loss of sensitivity to touch, vascular status, foot deformities,
and history of ulcer or amputation; referral of high risk patients for regular examination by
multidisciplinary team; provision of appropriate footware, insoles, skin and nail care, and foot
care education at each review
DM-5: Neuropathy screening and preventive foot care
MI=myocardial infarction, ACE=angiotensin converting enzyme.
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RESEARCHTable 2| Main epidemiological parameters used in analysis of cardiovascular disease, diabetes, and tobacco related disease rates in WHO
sub-Saharan African sub-region AfrE and South East Asian sub-region SearD*
Age groups in SearD (years) Age groups in AfrE (years)
Model parameter ≥80 70–79 60–69 45–59 30–44 ≥80 70–79 60–69 45–59 30–44
Disease incidence (per 1000 population)
11.8 9.67 8.46 3.91 0.67 8.20 6.02 4.55 2.08 0.31 Men Ischaemic heart
disease
6.67 6.82 5.47 2.00 0.42 4.72 3.34 2.53 1.02 0.14 Women
15.3 14.7 9.38 2.70 0.34 20.1 13.0 6.86 2.93 0.87 Men Cerebrovascular
disease
14.9 9.96 5.58 1.93 0.19 22.5 12.3 5.74 3.33 0.91 Women
1.39 2.45 2.53 2.37 3.22 0.48 1.15 1.97 2.30 2.90 Men Diabetes
0.29 1.21 2.15 2.61 4.02 0.44 1.17 1.97 3.00 2.80 Women
10.9 9.00 8.30 2.10 0.54 9.78 5.43 4.62 1.43 0.18 Men COPD
9.24 6.85 4.32 2.27 0.33 4.29 2.25 1.06 0.40 0.10 Women
Disease prevalence (per 1000 population)
2.64 2.09 1.75 0.78 0.11 1.64 1.37 0.93 0.38 0.49 Men Ischaemic heart
disease
1.39 1.46 1.16 0.40 0.08 1.16 0.87 0.63 0.22 0.02 Women
0.61 0.36 0.18 0.09 0.01 0.56 0.38 0.18 0.07 0.02 Men Cerebrovascular
disease
0.45 0.30 0.16 0.05 0.01 0.61 0.36 0.18 0.09 0.01 Women
107 105 76.0 43.2 29.6 47.0 48.2 49.2 39.6 17.0 Men Diabetes
76.5 91.7 80.2 49.7 31.4 34.9 41.4 47.9 37.3 15.3 Women
25.6 45.0 32.1 45.5 5.92 31.6 30.2 27.5 9.20 1.54 Men COPD
17.0 19.7 20.8 40.4 3.45 7.85 7.96 6.70 2.61 0.30 Women
Disease mortality (per 1000 population)
33.9 18.5 9.32 2.81 0.37 23.3 11.8 5.09 1.56 0.18 Men Ischaemic heart
disease
27.9 15.2 6.76 1.46 0.25 18.5 7.69 3.15 0.79 0.09 Women
18.3 9.95 4.52 0.90 0.08 24.4 9.87 4.02 1.32 0.29 Men Cerebrovascular
disease
20.4 9.95 3.69 0.62 0.05 31.5 12.2 4.11 1.27 0.31 Women
1.37 2.57 2.16 0.97 0.42 0.45 1.32 1.74 1.98 1.13 Men Diabetes
1.15 3.66 2.80 1.13 0.58 0.84 2.19 2.13 1.76 1.51 Women
9.95 8.33 3.10 1.64 0.09 11.4 5.40 2.67 0.58 0.08 Men COPD
7.55 4.09 2.02 1.47 0.05 4.68 2.13 0.88 0.20 0.03 Women
Risk factor epidemiology
136 134 132 128 123 139 137 134 129 122 Men Mean systolic
blood pressure
(mmHg)
137 134 131 126 120 140 139 135 128 118 Women
4.70 5.06 5.18 5.19 5.01 4.63 4.76 4.76 4.65 4.36 Men Mean cholesterol
level (mmol/L)
5.57 5.63 5.58 5.44 5.05 5.07 5.04 4.94 4.71 4.28 Women
20.1 21.0 21.6 22.4 22.3 21.1 21.8 22.3 22.5 21.8 Men Meanbodymass
index (kg/m
2)
21.6 22.2 22.3 22.1 21.3 23.0 23.3 23.6 23.7 23.2 Women
12.3 12.3 12.3 12.3 12.0 8.13 8.13 8.13 8.13 8.48 Men Mean salt intake
(g/day)
10.6 10.6 10.6 10.6 10.9 8.00 8.00 8.00 8.00 9.8 Women
17.3 17.5 20.6 24.2 32.3 6.16 6.15 7.06 7.35 13.5 Men Smoking
prevalence (%)
0.53 1.45 3.52 4.09 0.81 0.67 0.87 1.38 1.56 1.19 Women
0.16 0.16 0.19 0.22 0.31 0.08 0.08 0.10 0.12 0.13 Men Smoking impact
ratio
0.01 0.01 0.03 0.04 0.01 0.03 0.03 0.04 0.05 0.06 Women
COPD = Chronic obstructive pulmonary disease.
*Data sources: Mathers et al
47; Ezzati et al
48.
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RESEARCHTable 3| Relative risks for disease (per unit increase in risk factor) used in analysis of cardiovascular disease, diabetes, and tobacco related
disease rates in WHO sub-Saharan African sub-region AfrE and South East Asian sub-region SearD*
Age group (years)
Risk factors and associated disease risks ≥80 70–79 60–69 45–59 30–44
Systolic blood pressure (mm Hg)
Relative risk for disease:
1.01 1.02 1.03 1.05 1.07 Ischaemic heart disease
1.02 1.03 1.05 1.07 1.09 Cerebrovascular disease (stroke)
Cholesterol (mmol/L)
Relative risk for disease:
1.42 1.42 1.55 2.08 3.65 Ischaemic heart disease
1.09 1.17 1.25 1.35 1.48 Cerebrovascular disease (stroke)
Body mass index (kg/m
2)
Relative risk for disease:
1.03 1.04 1.05 1.09 1.11 Ischaemic heart disease
1.02 1.06 1.06 1.09 1.19 Cerebrovascular disease (stroke)
Smoking
Relative risk for disease:
1.65 1.65 1.65 3.12 3.12 Stroke
1.38 1.70 1.84 2.43 2.43 Ischaemic heart disease and stroke
5.73 5.73 5.73 6.43 6.43 Ischaemic heart disease and COPD
2.50 2.50 3.00 3.00 3.00 Mortality, males (cancer effect)
1.70 1.70 1.80 1.80 1.80 Mortality, females (cancer effect)
*Data sources: WHO 2002
26; Murray and Lopez 1996
31
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e607 doi: 10.1136/bmj.e607 (Published 2 March 2012) Page 12 of 15
RESEARCHTable 4| Results for the less costly and most effective interventions to combat cardiovascular disease, diabetes, and tobacco related
disease rates in WHO sub-Saharan African sub-region AfrE and South East Asian sub-region SearD
WHO Asian sub-region SearD WHO African sub-region AfrE
Cost effectiveness ratio
Annual
cost per
capita
($Int)
Annual
DALYs
saved per
million
population
Cost effectiveness ratio
Annual
cost per
capita
($Int)
Annual
DALYs
saved per
million
population Incremental† Average* Incremental† Average*
CVD prevention: control of tobacco use
87 87 0.27 3043 448 448 0.31 687 TOB-2: Increased taxation
156 98 0.36 3617 Dominated‡ 552 0.42 768 TOB-10: As TOB-2 + clean indoor
air legislation
182 112 0.48 4300 1384 658 0.58 885 TOB-15: As TOB-10 + tobacco
advertising ban
198 128 0.68 5296 1645 815 0.86 1051 TOB-27: As TOB-15 + information
and labelling
4176 154 0.82 5330 Dominated‡ 894 0.94 1052 TOB-35: As TOB-27 + brief advice
to quit
4229 163 0.87 5342 28 082 927 0.98 1056 TOB-36: As TOB-27 + counselling
to quit
CVD prevention and treatment
81 81 0.03 402 Dominated‡ 626 0.06 96 CVD-29: Treatment of CHF with
diuretics
146 138 0.41 2984 104 104 0.33 3163 CVD-11: Preventive multidrug
treatment for >35% risk of CVD
event
152 142 0.62 4386 129 112 0.52 4649 CVD-77: As CVD-11 + multidrug
treatment of post-acute IHD & stroke
+ diuretics & exercise for CHF
404 175 0.88 5016 158 117 0.62 5265 CVD-78: As CVD-11 + multidrug
treatment of acute MI or post-acute
IHD & stroke + diuretics & exercise
for CHF
462 216 1.27 5857 1165 149 0.81 5431 CVD-73: Preventive multidrug
treatment for >25% risk of CVD
event + multidrug treatment of acute
MI or post-acute IHD & stroke +
diuretics & exercise for CHF
1817 528 3.84 7271 3931 401 2.33 5817 CVD-8: Preventive multidrug
treatment for >5% risk of CVD event
Treatment of diabetes and its complications
170 170 0.32 1891 814 814 1.00 1228 DM-4: Retinopathy screening +
photocoagulation
2399 512 1.14 2233 4266 1375 2.02 1467 DM-6: As DM-4 + standard
glycaemic control
11 348 912 2.11 2319 18 419 2070 3.17 1529 DM-8: As DM-4 + intensive
glycaemic control
DALYs=disability adjusted life years. $Int=international dollars.
*$Int per DALY averted relative to no intervention.
†$Int per DALY averted, within intervention cluster
‡These interventions are not dominant strategies and results are therefore not included here.
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RESEARCHFigures
Fig 1 Cost effectiveness of interventions for cardiovascular disease, diabetes, and tobacco use for WHO African sub-region
AfrE
Fig 2 Cost effectiveness of interventions for cardiovascular disease, diabetes, and tobacco use for WHO South-East Asian
sub-region SearD
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RESEARCHFig 3 Probabilistic uncertainty graph for the less costly and most effective interventions for cardiovascular disease, diabetes,
and tobacco use in WHO South East Asia sub-region SearD. See table 4⇓ for explanation of intervention codes
Fig 4 Probabilistic uncertainty graph for the less costly and most effective interventions for cardiovascular disease, diabetes,
and tobacco use in WHO African sub-region AfrE. See table 4⇓ for explanation of intervention codes
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